National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)
Patient VersionHealth Professional VersionEn españolLast Modified: 08/22/2007



General Information






Classification of Pediatric Myeloid Malignancies






Stage Information






Treatment Overview for Acute Myeloid Leukemia






Treatment of Newly Diagnosed Acute Myeloid Leukemia






Postremission Therapy for Acute Myeloid Leukemia






Acute Promyelocytic Leukemia






Children With Down Syndrome






Myelodysplastic Syndromes






Juvenile Myelomonocytic Leukemia






Chronic Myelogenous Leukemia






Recurrent Childhood Acute Myeloid Leukemia






Survivorship and Adverse Late Sequelae






Get More Information From NCI







Changes to This Summary (08/22/2007)






More Information



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
New Study of Targeted Therapies for Breast Cancer

The Nation's Investment in Cancer Research FY 2009

President's Cancer Panel Annual Report: 2006-2007

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
Changes to This Summary (08/22/2007)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Classification of Pediatric Myeloid Malignancies

Added Meshinchi et al. as reference 52.

Added Chou et al. as reference 74.

Added Thiede et al. as reference 75.

Added text stating that immunohistochemical methods can be used to accurately identify patients with nucleophosmin mutations.

Added Falini et al. as reference 77.

Treatment Overview for Acute Myeloid Leukemia

Added text stating that the Berlin-Frankfurt-Munster 98 study confirmed a lack of benefit for the use of granulocyte colony-stimulating factor (cited Lehrnbecher et al. as reference 9).

Treatment of Newly Diagnosed Acute Myeloid Leukemia

Added Creutzig et al. as reference 13.

Postremission Therapy for Acute Myeloid Leukemia

Added text stating that indications for autologous and allogenic hematopoietic stem cell transplantation have been published (cited Oliansky et al. as reference 6).

Back to TopBack to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov